Crystal nephropathies: Mechanisms of crystal-induced kidney injury

Nature Reviews Nephrology

Volumn 13, Issue 4, 2017, Pages 226-240

  Mulay, Shrikant R ^a   Anders, Hans Joachim ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BILE SALT; BILIRUBIN; INTERLEUKIN 1BETA;

ACUTE KIDNEY FAILURE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CHOLESTEROL EMBOLISM; CLINICAL FEATURE; CRYSTAL CYTOTOXICITY; CRYSTAL INDUCED KIDNEY INJURY; CRYSTAL NEPHROPATHY; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; HUMAN; KIDNEY COLIC; KIDNEY DISEASE; NEPHRITIS; NEPHROANGIOSCLEROSIS; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RENOVASCULAR CRYSTALLOPATHY; REVASCULARIZATION; REVIEW; RISK FACTOR; STONE FORMATION; TUBULAR CRYSTALLOPATHY; URINARY TRACT; URINARY TRACT CRYSTALLOPATHY; UROLITHIASIS; VASCULARIZATION; ACUTE KIDNEY INJURY; CRYSTALLIZATION; KIDNEY DISEASES; RENAL INSUFFICIENCY, CHRONIC;

ACUTE KIDNEY INJURY; CRYSTALLIZATION; HUMANS; KIDNEY DISEASES; RENAL INSUFFICIENCY, CHRONIC;

EID: 85013187608     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2017.10     Document Type: Review

References (160)

1. Marangella, M. et al. Crystallization inhibitors in the pathophysiology and treatment of nephrolithiasis. Urol. Int. 72 (Suppl. 1), 6-10 (2004)
2. Kumar, V. &Lieske, J. C. Protein regulation of intrarenal crystallization. Curr. Opin. Nephrol. Hypertens. 15, 374-380 (2006)
3. Strowig, T., Henao-Mejia, J., Elinav, E. &Flavell, R. Inflammasomes in health and disease. Nature 481, 278-286 (2012)
4. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. &Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241 (2006)
5. Mulay, S. R. et al. Calcium oxalate crystals induce renal inflammation by NLRP3 mediated IL 1beta secretion. J. Clin. Invest. 123, 236-246 (2013)
6. Knauf, F. et al. NALP3 mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. Kidney Int. 84, 895-901 (2013)
7. Kurts, C. A crystal-clear mechanism of chronic kidney disease. Kidney Int. 84, 859-861 (2013)
8. Mulay, S. R. &Anders, H. J. Crystallopathies. N. Engl. J. Med. 374, 2465-2476 (2016)
9. Mulay, S. R. et al. Cytotoxicity of crystals involves RIPK3 MLKL-mediated necroptosis. Nat. Commun. 7, 10274 (2016)
10. Gutierrez Solis, E. et al. Atheroembolic renal disease: analysis of clinical and therapeutic factors that influence its progression. Nefrologia 30, 317-323 (in Spanish) (2010)
11. Kronzon, I. &Saric, M. Cholesterol embolization syndrome. Circulation 122, 631-641 (2010)
12. Meola, M. &Petrucci, I. Color Doppler sonography in the study of chronic ischemic nephropathy. J. Ultrasound 11, 55-73 (2008)
13. Haas, M., Spargo, B. H., Wit, E. J. &Meehan, S. M. Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. Am. J. Kidney Dis. 35, 433-447 (2000)
14. Abela, G. S. Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation. J. Clin. Lipidol. 4, 156-164 (2010)
15. Scolari, F. et al. The challenge of diagnosing atheroembolic renal disease: clinical features and prognostic factors. Circulation 116, 298-304 (2007)
16. Pilely, K. et al. Cholesterol crystals activate the lectin complement pathway via ficolin 2 and mannose-binding lectin: implications for the progression of atherosclerosis. J. Immunol. 196, 5064-5074 (2016)
17. Dupont, P. J. et al. Lesson of the week: cholesterol emboli syndrome. BMJ 321, 1065-1067 (2000)
18. Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357-1361 (2010)
19. Samstad, E. O. et al. Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release. J. Immunol. 192, 2837-2845 (2014)
20. Kiyotake, R. et al. Human mincle binds to cholesterol crystals and triggers innate immune responses. J. Biol. Chem. 290, 25322-25332 (2015)
21. Gore, I., McCombs, H. L. &Lindquist, R. L. Observations on the fate of cholesterol emboli. J. Atheroscler. Res. 4, 527-535 (1964)
22. Warren, B. A. &Vales, O. Electron microscopy of the sequence of events in the atheroembolic occlusion of cerebral arteries in an animal model. Br. J. Exp. Pathol. 56, 205-215 (1975)
23. Warren, B. A. &Vales, O. The ultrastructure of the reaction of arterial walls to cholesterol crystals in atheroembolism. Br. J. Exp. Pathol. 57, 67-77 (1976)
24. Scolari, F. &Ravani, P. Atheroembolic renal disease. Lancet 375, 1650-1660 (2010)
25. Scolari, F. et al. Predictors of renal and patient outcomes in atheroembolic renal disease: a prospective study. J. Am. Soc. Nephrol. 14, 1584-1590 (2003)
26. Meyrier, A. Hypertensive nephrosclerosis pathogenesis, diagnosis and management. Saudi J. Kidney Dis. Transpl. 10, 267-274 (1999)
27. Quinones, A. &Saric, M. The cholesterol emboli syndrome in atherosclerosis. Curr. Atheroscler. Rep. 15, 315 (2013)
28. Etemadi, J. et al. Renal artery stenosis in kidney transplants: assessment of the risk factors. Vasc. Health Risk Manag. 7, 503-507 (2011)
29. Kwon, S. H. &Lerman, L. O. Atherosclerotic renal artery stenosis: current status. Adv. Chron. Kidney Dis. 22, 224-231 (2015)
30. Paloian, N. J. &Giachelli, C. M. A current understanding of vascular calcification in CKD. Am. J. Physiol. Renal Physiol. 307, F891-F900 (2014)
31. Leopold, J. A. Vascular calcification: mechanisms of vascular smooth muscle cell calcification. Trends Cardiovasc. Med. 25, 267-274 (2015)
32. The ASTRAL Investigators et al. Revascularization versus medical therapy for renal-artery stenosis. N. Engl. J. Med. 361, 1953-1962 (2009)
33. Zimmer, S. et al. Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming. Sci Transl Med. 8, 333ra50 (2016)
34. US National Library of Medicine. Clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT02534844 (2017)
35. Herlitz, L. C., D'Agati, V. D. &Markowitz, G. S. Crystalline nephropathies. Arch. Pathol. Lab. Med. 136, 713-720 (2012)
36. Doshi, M. et al. Paraprotein-related kidney disease: kidney injury from paraproteins-what determines the site of injury? Clin. J. Am. Soc. Nephrol. 11, 2288-2294 (2016)
37. Bridoux, F. et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int. 87, 698-711 (2015)
38. Khalighi, M. A., Dean Wallace, W. &Palma-Diaz, M. F. Amyloid nephropathy. Clin. Kidney J. 7, 97-106 (2014)
39. Motwani, S. S. et al. Paraprotein-related kidney disease: glomerular diseases associated with paraproteinemias. Clin. J. Am. Soc. Nephrol. 11, 2260-2272 (2016)
40. Salit, R. B. &Bishop, M. R. The evolving world of tumor lysis syndrome. Oncology (Williston Park) 25, 378-380 (2011)
41. Kaler, B. et al. Are bile acids involved in the renal dysfunction of obstructive jaundice? An experimental study in bile duct ligated rats. Ren. Fail. 26, 507-516 (2004)
42. Morgan, W. A., Dingg, Y. &Bach, P. H. The relationship between sodium chloride concentration and bile acid cytotoxicity in cultured kidney cells. Ren. Fail. 20, 441-450 (1998)
43. van Slambrouck, C. M., Salem, F., Meehan, S. M. &Chang, A. Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction. Kidney Int. 84, 192-197 (2013)
44. Worcester, E. M. &Coe, F. L. Clinical practice. Calcium kidney stones. N. Engl. J. Med. 363, 954-963 (2010)
45. Robijn, S., Hoppe, B., Vervaet, B. A., D'Haese, P. C. &Verhulst, A. Hyperoxaluria: a gut-kidney axis? Kidney Int. 80, 1146-1158 (2011)
46. Syed, F., Mena-Gutierrez, A. &Ghaffar, U. A case of iced-tea nephropathy. N. Engl. J. Med. 372, 1377-1378 (2015)
47. Albersmeyer, M. et al. Acute kidney injury after ingestion of rhubarb: secondary oxalate nephropathy in a patient with type 1 diabetes. BMC Nephrol. 13, 141 (2012)
48. Karaolanis, G., Lionaki, S., Moris, D., Palla, V. V. &Vernadakis, S. Secondary hyperoxaluria: a risk factor for kidney stone formation and renal failure in native kidneys and renal grafts. Transplant. Rev. (Orlando) 28, 182-187 (2014)
49. Nankivell, B. J. &Murali, K. M. Images in clinical medicine. Renal failure from vitamin C after transplantation. N. Engl. J. Med. 358, e4 (2008)
50. Morfin, J. &Chin, A. Images in clinical medicine. Urinary calcium oxalate crystals in ethylene glycol intoxication. N. Engl. J. Med. 353, e21 (2005)
51. Hoffmanova, I., Kraml, P. &Andel, M. Renal risk associated with sodium phosphate medication: safe in healthy individuals, potentially dangerous in others. Expert Opin. Drug Saf. 14, 1097-1110 (2015)
52. Gagnon, R. F., Alli, A. I., Watters, A. K. &Tsoukas, C. M. Indinavir crystalluria. Kidney Int. 70, 2047 (2006)
53. Hess, B. Drug-induced urolithiasis. Curr. Opin. Urol. 8, 331-334 (1998)
54. Roncal-Jimenez, C. et al. Heat stress nephropathy from exercise-induced uric acid crystalluria: a perspective on Mesoamerican nephropathy. Am. J. Kidney Dis. 67, 20-30 (2016)
55. Gois, P. H. et al. Allopurinol attenuates rhabdomyolysis-associated acute kidney injury: renal and muscular protection. Free Radic. Biol. Med. 101, 176-189 (2016)
56. Vanholder, R., Sever, M. S., Erek, E. &Lameire, N. Rhabdomyolysis. J. Am. Soc. Nephrol. 11, 1553-1561 (2000)
57. Pasnoor, M., Barohn, R. J. &Dimachkie, M. M. Toxic myopathies. Neurol. Clin. 32, 647-670 (2014)
58. Oliveira, B., Kleta, R., Bockenhauer, D. &Walsh, S. B. Genetic, pathophysiological and clinical aspects of nephrocalcinosis. Am J Physiol. Renal Physiol. 311, F1243-F1252 (2016)
59. Devuyst, O. et al. Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet 383, 1844-1859 (2014)
60. Gunal, A. I. et al. Early and vigorous fluid resuscitation prevents acute renal failure in the crush victims of catastrophic earthquakes. J. Am. Soc. Nephrol. 15, 1862-1867 (2004)
61. Terlinsky, A. S., Grochowski, J., Geoly, K. L., Strauch, B. S. &Hefter, L. Monohydrate calcium oxalate crystalluria in ethylene glycol poisoning. N. Engl. J. Med. 302, 922 (1980)
62. Linkermann, A., Stockwell, B. R., Krautwald, S. &Anders, H. J. Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat. Rev. Immunol. 14, 759-767 (2014)
63. Tan, M. &Epstein, W. Polymer formation during the degradation of human light chain and Bence-Jones proteins by an extrct of the lysosomal fraction of normal human kidney. Immunochemistry 9, 9-16 (1972)
64. Liu, Z. et al. Calcium phosphate nanoparticles primarily induce cell necrosis through lysosomal rupture: the origination of material cytotoxicity. J. Mater. Chem. B. 2, 3480-3489 (2014)
65. Huang, D., Zhou, H. &Gao, J. Nanoparticles modulate autophagic effect in a dispersity-dependent manner. Sci. Rep. 5, 14361 (2015)
66. Linkermann, A. &Green, D. R. Necroptosis. N. Engl. J. Med. 370, 455-465 (2014)
67. Kroemer, G. et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 16, 3-11 (2009)
68. Fortes, G. B. et al. Heme induces programmed necrosis on macrophages through autocrine TNF and ROS production. Blood 119, 2368-2375 (2012)
69. Desai, J. et al. PMA and crystal-induced neutrophil extracellular trap formation involves RIPK1 RIPK3 MLKL signaling. Eur. J. Immunol. 46, 223-229 (2016)
70. Linkermann, A. et al. Synchronized renal tubular cell death involves ferroptosis. Proc. Natl Acad. Sci. USA 111, 16836-16841 (2014)
71. Rock, K. L., Latz, E., Ontiveros, F. &Kono, H. The sterile inflammatory response. Annu. Rev. Immunol. 28, 321-342 (2010)
72. Allam, R., Kumar, S. V., Darisipudi, M. N. &Anders, H. J. Extracellular histones in tissue injury and inflammation. J. Mol. Med. (Berl) 92, 465-472 (2014)
73. Franklin, B. S., Mangan, M. S. &Latz, E. Crystal formation in inflammation. Annu. Rev. Immunol. 34, 173-202 (2016)
74. Hari, A. et al. Activation of NLRP3 inflammasome by crystalline structures via cell surface contact. Sci. Rep. 4, 7281 (2014)
75. Schorn, C. et al. Sodium overload and water influx activate the NALP3 inflammasome. J. Biol. Chem. 286, 35-41 (2011)
76. Gross, O. et al. Inflammasome activators induce interleukin 1alpha secretion via distinct pathways with differential requirement for the protease function of caspase 1. Immunity 36, 388-400 (2012)
77. Hornung, V. et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9, 847-856 (2008)
78. Halle, A. et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 9, 857-865 (2008)
79. Heneka, M. T. et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493, 674-678 (2013)
80. Anders, H. J. Of inflammasomes and alarmins: IL 1beta and IL 1alpha in kidney disease. J. Am. Soc. Nephrol. 27, 2564-2575 (2016)
81. Dinarello, C. A. The role of the interleukin 1 receptor antagonist in blocking inflammation mediated by interleukin 1. N. Engl. J. Med. 343, 732-734 (2000)
82. Ng, G. et al. Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells. Immunity 29, 807-818 (2008)
83. Arai, S. et al. Apoptosis inhibitor of macrophage protein enhances intraluminal debris clearance and ameliorates acute kidney injury in mice. Nat. Med. 22, 183-193 (2016)
84. Mulay, S. R., Evan, A. &Anders, H. J. Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease. Nephrol. Dial. Transplant. 29, 507-514 (2014)
85. Xiao, J. et al. Soluble uric acid increases NALP3 inflammasome and interleukin 1beta expression in human primary renal proximal tubule epithelial cells through the Toll-like receptor 4 mediated pathway. Int. J. Mol. Med. 35, 1347-1354 (2015)
86. Noda, S. On mechanism of urate kidney stone formation. Scan. Electron Microsc. 4, 1801-1808 (1984)
87. Mandel, N. Crystal-membrane interaction in kidney stone disease. J. Am. Soc. Nephrol. 5, S37-S45 (1994)
88. Asselman, M., Verhulst, A., Broe, M. E. &Verkoelen, C. F. Calcium oxalate crystal adherence to hyaluronan-, osteopontin-, and CD44 expressing injured/regenerating tubular epithelial cells in rat kidneys. J. Am. Soc. Nephrol. 14, 3155-3166 (2003)
89. Bigelow, M. W., Wiessner, J. H., Kleinman, J. G. &Mandel, N. S. Surface exposure of phosphatidylserine increases calcium oxalate crystal attachment to IMCD cells. Am. J. Physiol. 272, F55-F62 (1997)
90. Carr, G., Simmons, N. L. &Sayer, J. A. Disruption of clc 5 leads to a redistribution of annexin A2 and promotes calcium crystal agglomeration in collecting duct epithelial cells. Cell. Mol. Life Sci. 63, 367-377 (2006)
91. Tischler, V., Schuurmans, M. M., Boehler, A. &Gaspert, A. Crystal precipitation and granulomatous inflammation in multiple organs after foscarnet therapy in a lung transplant recipient. J. Heart Lung Transplant. 31, 1037-1040 (2012)
92. Okabe, C. et al. NF kappaB activation mediates crystal translocation and interstitial inflammation in adenine overload nephropathy. Am. J. Physiol. Renal Physiol. 305, F155-F163 (2013)
93. Ayoub, I. et al. Revisiting medullary tophi: a link between uric acid and progressive chronic kidney disease? Clin. Nephrol. 85, 109-113 (2016)
94. Vervaet, B. A., Verhulst, A., Dauwe, S. E., De Broe, M. E. &D'Haese, P. C. An active renal crystal clearance mechanism in rat and man. Kidney Int. 75, 41-51 (2009)
95. Vervaet, B. A., Verhulst, A., D'Haese, P. C. &De Broe, M. E. Nephrocalcinosis: new insights into mechanisms and consequences. Nephrol. Dial. Transplant. 24, 2030-2035 (2009)
96. Bruijn, W. C. et al. Etiology of calcium oxalate nephrolithiasis in rats. I. Can this be a model for human stone formation? Scanning Microsc. 9, 103-114 (1995)
97. Correa-Costa, M. et al. Macrophage trafficking as key mediator of adenine-induced kidney injury. Mediators Inflamm. 2014, 291024 (2014)
98. Taguchi, K. et al. M1/M2 macrophage phenotypes regulate renal calcium oxalate crystal development. Sci. Rep. 6, 35167 (2016)
99. Kim, Y. G. et al. Involvement of macrophage migration inhibitory factor (MIF) in experimental uric acid nephropathy. Mol. Med. 6, 837-848 (2000)
100. Kusmartsev, S. et al. Calcium oxalate stone fragment and crystal phagocytosis by human macrophages. J. Urol. 195, 1143-1151 (2016)
101. Okada, A. et al. Genome-wide analysis of genes related to kidney stone formation and elimination in the calcium oxalate nephrolithiasis model mouse: detection of stone-preventive factors and involvement of macrophage activity. J. Bone Miner. Res. 24, 908-924 (2009)
102. Okada, A. et al. Renal macrophage migration and crystal phagocytosis via inflammatory-related gene expression during kidney stone formation and elimination in mice: Detection by association analysis of stone-related gene expression and microstructural observation. J. Bone Miner. Res. 25, 2701-2711 (2010)
103. Taguchi, K. et al. Colony-stimulating factor 1 signaling suppresses renal crystal formation. J. Am. Soc. Nephrol. 25, 1680-1697 (2014)
104. Helming, L. &Gordon, S. Molecular mediators of macrophage fusion. Trends Cell Biol. 19, 514-522 (2009)
105. Marakalala, M. J. et al. Inflammatory signaling in human tuberculosis granulomas is spatially organized. Nat. Med. 22, 531-538 (2016)
106. Ermer, T., Eckardt, K. U., Aronson, P. S. &Knauf, F. Oxalate, inflammasome, and progression of kidney disease. Curr. Opin. Nephrol. Hypertens. 25, 363-371 (2016)
107. Wang, W. et al. Inflammasome-independent NLRP3 augments TGF-beta signaling in kidney epithelium. J. Immunol. 190, 1239-1249 (2013)
108. Vilaysane, A. et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J. Am. Soc. Nephrol. 21, 1732-1744 (2010)
109. Lech, M. et al. NLRP3 and ASC suppress lupus-like autoimmunity by driving the immunosuppressive effects of TGF-beta receptor signalling. Ann. Rheum. Dis. 74, 2224-2235 (2015)
110. Lorenz, G., Darisipudi, M. N. &Anders, H. J. Canonical and non-canonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis. Nephrol. Dial. Transplant. 29, 41-48 (2014)
111. Ludwig-Portugall, I. et al. An NLRP3 specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice. Kidney Int. 90, 525-539 (2016)
112. Coiffier, B., Altman, A., Pui, C. H., Younes, A. &Cairo, M. S. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J. Clin. Oncol. 26, 2767-2778 (2008)
113. Jones, G. L. et al. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br. J. Haematol. 169, 661-671 (2015)
114. Allen, K. C. et al. Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) project. Drug Saf. 38, 183-187 (2015)
115. Mulay, S. R., Linkermann, A. &Anders, H. J. Necroinflammation in kidney disease. J. Am. Soc. Nephrol. 27, 27-39 (2016)
116. Mulay, S. R., Holderied, A., Kumar, S. V. &Anders, H. J. Targeting inflammation in so called acute kidney injury. Semin. Nephrol. 36, 17-30 (2016)
117. Mulay, S. R., Kumar, S. V., Lech, M., Desai, J. &Anders, H. J. How kidney cell death induces renal necroinflammation. Semin. Nephrol. 36, 162-173 (2016)
118. Mulay, S. R. et al. Hyperoxaluria requires TNF receptors to initiate crystal adhesion and kidney stone disease. J. Am. Soc. Nephrol. http://dx.doi. org/10.1681/ASN.2016040486 (2016)
119. Scales, C. D. et al. Prevalence of kidney stones in the United States. Eur. Urol. 62, 160-165 (2012)
120. Sayer, J. A. Progress in understanding the genetics of calcium-containing nephrolithiasis. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ ASN.2016050576 (2016)
121. Correa-Rotter, R., Wesseling, C. &Johnson, R. J. CKD of unknown origin in Central America: the case for a Mesoamerican nephropathy. Am. J. Kidney Dis. 63, 506-520 (2014)
122. Miller, D. C. &Wolf, J. S. Jr. Acute renal colic. N. Engl. J. Med. 350, 2422-2423 (2004)
123. Song, Y., Hernandez, N., Gee, M. S., Noble, V. E. &Eisner, B. H. Can ureteral stones cause pain without causing hydronephrosis? World J. Urol. 34, 1285-1288 (2016)
124. Coe, F. L., Worcester, E. M. &Evan, A. P. Idiopathic hypercalciuria and formation of calcium renal stones. Nat. Rev. Nephrol. 12, 519-533 (2016)
125. Dursun, M., Ozbek, E., Otunctemur, A., Sahin, S. &Cakir, S. S. Clinical presentation of urolithiasis in older and younger population. Arch. Ital. Urol. Androl. 86, 249-252 (2014)
126. Randall, A. The origin and growth of renal calculi. Ann. Surg. 105, 1009-1027 (1937)
127. Evan, A. P. et al. Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J. Clin. Invest. 111, 607-616 (2003)
128. Stoller, M. L., Meng, M. V., Abrahams, H. M. &Kane, J. P. The primary stone event: a new hypothesis involving a vascular etiology. J. Urol. 171, 1920-1924 (2004)
129. Williams, J. C. Jr et al. Calcium oxalate calculi found attached to the renal papilla: preliminary evidence for early mechanisms in stone formation. J. Endourol. 20, 885-890 (2006)
130. Kumar, V. et al. Cell biology of pathologic renal calcification: contribution of crystal transcytosis, cell-mediated calcification, and nanoparticles. J. Investig. Med. 54, 412-424 (2006)
131. Evan, A. P. et al. Mechanism of formation of human calcium oxalate renal stones on Randall's plaque. Anat. Rec. (Hoboken) 290, 1315-1323 (2007)
132. Kumar, V., Pena Vega, L., Farell, G. &Lieske, J. C. Urinary macromolecular inhibition of crystal adhesion to renal epithelial cells is impaired in male stone formers. Kidney Int. 68, 1784-1792 (2005)
133. Robertson, W. G. Potential role of fluctuations in the composition of renal tubular fluid through the nephron in the initiation of Randall's plugs and calcium oxalate crystalluria in a computer model of renal function. Urolithiasis 43 (Suppl. 1), 93-107 (2015)
134. Verkoelen, C. F., van der Boom, B. G., Houtsmuller, A. B., Schroder, F. H. &Romijn, J. C. Increased calcium oxalate monohydrate crystal binding to injured renal tubular epithelial cells in culture. Am. J. Physiol. 274, F958-F965 (1998)
135. Verkoelen, C. F. et al. Cell type-specific acquired protection from crystal adherence by renal tubule cells in culture. Kidney Int. 55, 1426-1433 (1999)
136. Mulay, S. R. et al. Oxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57BL/6 mice. Am. J. Physiol. Renal Physiol. 310, F785-F795 (2016)
137. Evan, A. P. Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr. Nephrol. 25, 831-841 (2010)
138. Kok, D. J. &Khan, S. R. Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int. 46, 847-854 (1994)
139. Evan, A. P. et al. Renal crystal deposits and histopathology in patients with cystine stones. Kidney Int. 69, 2227-2235 (2006)
140. Evan, A. P., Worcester, E. M., Coe, F. L., Williams, J. Jr &Lingeman, J. E. Mechanisms of human kidney stone formation. Urolithiasis 43 (Suppl. 1), 19-32 (2015)
141. Khan, S. R. &Canales, B. K. Unified theory on the pathogenesis of Randall's plaques and plugs. Urolithiasis 43 (Suppl. 1), 109-123 (2015)
142. Sharma, M., Kaur, T. &Singla, S. K. Role of mitochondria and NADPH oxidase derived reactive oxygen species in hyperoxaluria induced nephrolithiasis: therapeutic intervention with combinatorial therapy of N acetyl cysteine and Apocynin. Mitochondrion 27, 15-24 (2016)
143. Huang, H. S., Ma, M. C., Chen, C. F. &Chen, J. Lipid peroxidation and its correlations with urinary levels of oxalate, citric acid, and osteopontin in patients with renal calcium oxalate stones. Urology 62, 1123-1128 (2003)
144. Huang, H. S., Chen, J., Chen, C. F. &Ma, M. C. Vitamin E attenuates crystal formation in rat kidneys: roles of renal tubular cell death and crystallization inhibitors. Kidney Int. 70, 699-710 (2006)
145. Khan, S. R. Is oxidative stress, a link between nephrolithiasis and obesity, hypertension, diabetes, chronic kidney disease, metabolic syndrome? Urol. Res. 40, 95-112 (2012)
146. Joshi, S., Saylor, B. T., Wang, W., Peck, A. B. &Khan, S. R. Apocynin-treatment reverses hyperoxaluria induced changes in NADPH oxidase system expression in rat kidneys: a transcriptional study. PLoS ONE 7, e47738 (2012)
147. Zuo, J., Khan, A., Glenton, P. A. &Khan, S. R. Effect of NADPH oxidase inhibition on the expression of kidney injury molecule and calcium oxalate crystal deposition in hydroxy-L proline-induced hyperoxaluria in the male Sprague-Dawley rats. Nephrol. Dial. Transplant. 26, 1785-1796 (2011)
148. Khan, S. R., Joshi, S., Wang, W. &Peck, A. B. Regulation of macromolecular modulators of urinary stone formation by reactive oxygen species: transcriptional study in an animal model of hyperoxaluria. Am. J. Physiol. Renal Physiol. 306, F1285-F1295 (2014)
149. Tsuji, H. et al. Involvement of renin-angiotensin-aldosterone system in calcium oxalate crystal induced activation of NADPH oxidase and renal cell injury. World J. Urol. 34, 89-95 (2016)
150. Umekawa, T., Hatanaka, Y., Kurita, T. &Khan, S. R. Effect of angiotensin II receptor blockage on osteopontin expression and calcium oxalate crystal deposition in rat kidneys. J. Am. Soc. Nephrol. 15, 635-644 (2004)
151. Toblli, J. E., Ferder, L., Stella, I., Angerosa, M. &Inserra, F. Protective role of enalapril for chronic tubulointerstitial lesions of hyperoxaluria. J. Urol. 166, 275-280 (2001)
152. Tungsanga, K., Sriboonlue, P., Futrakul, P., Yachantha, C. &Tosukhowong, P. Renal tubular cell damage and oxidative stress in renal stone patients and the effect of potassium citrate treatment. Urol. Res. 33, 65-69 (2005)
153. Becker, G. &Caring for Australians with Renal, I. The CARI guidelines. Kidney stones: uric acid stones. Nephrology (Carlton) 12 (Suppl. 1), S21-S25 (2007)
154. Mohayuddin, N. et al. The outcome of extracorporeal shockwave lithotripsy for renal pelvic stone with and without JJ stent-A comparative study. J. Pak. Med. Assoc. 59, 143-146 (2009)
155. Lu, Y., Ping, J. G., Zhao, X. J., Hu, L. K. &Pu, J. X. Randomized prospective trial of tubeless versus conventional minimally invasive percutaneous nephrolithotomy. World J. Urol. 31, 1303-1307 (2013)
156. Humphreys, M. R. et al. A new world revealed: early experience with digital ureteroscopy. J. Urol. 179, 970-975 (2008)
157. Giedelman, C. et al. Laparoscopic anatrophic nephrolithotomy: developments of the technique in the era of minimally invasive surgery. J. Endourol. 26, 444-450 (2012)
158. Moufid, K. et al. Large impacted upper ureteral calculi: a comparative study between retrograde ureterolithotripsy and percutaneous antegrade ureterolithotripsy in the modified lateral position. Urol. Ann. 5, 140-146 (2013)
159. El-Assmy, A. et al. Extracorporeal shock wave lithotripsy of upper urinary tract calculi in patients with cystectomy and urinary diversion. Urology 66, 510-513 (2005)
160. Prakash, J. et al. Retroperitoneoscopic versus open mini-incision ureterolithotomy for upper-and mid-ureteric stones: a prospective randomized study. Urolithiasis 42, 133-139 (2014)